Healthcare Providers and Services
Company Overview of Good Start Genetics, Inc.
Good Start Genetics, Inc., a molecular diagnostics company, provides genetic screening of inherited diseases. The company was founded in 2007 and is based in Cambridge, Massachusetts.
237 Putnam Avenue
Cambridge, MA 02139
Founded in 2007
Key Executives for Good Start Genetics, Inc.
Chief Executive Officer, President and Director
Co-Founder and Vice President of Business Development
Co-Founder and Vice President of Research & Technology
Chief Information Officer
Vice President of Human Resources & Administration
Compensation as of Fiscal Year 2015.
Good Start Genetics, Inc. Key Developments
Good Start Genetics, Inc. Presents at BIO International Convention 2015, Jun-17-2015 02:00 PM
Jun 11 15
Good Start Genetics, Inc. Presents at BIO International Convention 2015, Jun-17-2015 02:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Don M. Hardison, Chief Executive Officer, President and Director.
Good Start Genetics, Inc. Appoints Charles F. Wagner, Jr. to the Company's Board of Directors
Apr 28 14
Good Start Genetics, Inc. announced the appointment of Charles F. Wagner, Jr. to the company's board of directors. Mr. Wagner is currently chief financial officer and executive vice president, finance and administration of Bruker Corporation. Prior to Bruker, Mr. Wagner served as chief financial officer and executive vice president, finance and administration of Progress Software Corporation. Earlier, Mr. Wagner served as chief financial officer and vice president of Millipore Corporation.
Good Start Genetics Announces the Data from Validation Study and Clinical Data Demonstrating Accuracy of Their NGS-Based Carrier Screening Test
Jan 13 14
Good Start Genetics, Inc. announced the data from validation studies plus data from more than 11,000 patient samples tested in its clinical laboratory. The findings demonstrate that nearly 25% of the distinct pathogenic mutations and more than 5% of carriers detected by Good Start Genetics would have been missed by other commercially available genotyping screens utilizing traditional technologies. By arming physicians and patients with this actionable information, GoodStart Select(TM), the menu of carrier screening tests offered by Good Start Genetics, therefore has the potential to provide couples with greater certainty concerning their risk of conceiving a child with a debilitating or fatal inherited disease. The study, conducted by Good Start Genetics' team of clinical geneticists and scientists, evaluated 11,691 patients from in vitro fertilization (IVF) centers across the United States which used GoodStart Select screening tests, and identified 449 pathogenic mutations among 15 genes that are associated with 14 fatal or debilitating genetic diseases. Eighty-seven of these mutations were classified as distinct, and about one quarter of those would be missed by other commercially available genetic screening tests utilizing traditional, limited mutation panels, including 16 known mutations unique to GoodStart Select, and seven previously unreported mutations detected by this technology. More than 5% of patients that are carriers would have been missed if these traditional screening methods were used. By providing physicians and patients with additional actionable information, GoodStart Select has the potential to provide reproductive couples with greater certainty concerning their risk of conceiving a child with a debilitating or fatal genetic disorder.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|